Dirk Sibbing/LinkedIn
Nov 17, 2025, 05:31
Dirk Sibbing: New Data Strengthen the Case for Prasugrel in ACS
Dirk Sibbing, Professor, Cardiologist and Angiologist at Lauterbacher Mill Private Clinic and LMU Munich, shared on LinkedIn:
”Following ISAR-REACT 5 and the recently published large Danisch registry in > 10,000 pts more data is accumulating that benefits praugrel over ticagrelor for PCI in ACS patients.
See the interesting coverage and analysis with comments from Sripal Bangalore and Ajay Kirtane on TCTMD on TUXEDO-2, a randomized comparison that focused on diabetic patients with multivessel disease undergoing PCI.”
Find more information here.

Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Nov 21, 2026, 08:36Sangwan Sim: ASH 2026 to Highlight Research into PU.1-Related Neutrophil Dysfunction
-
Nov 21, 2026, 08:29Liz Tate: First Percutaneous LAAO Procedure Performed at The Park Hospital for Stroke Prevention
-
Nov 21, 2026, 08:26Robert Sidonio: WFH Webinar to Address Key Challenges in Rare Bleeding Disorders Care
-
Nov 21, 2026, 08:21Jenni Majumdar: What Changing Blood Transfusion Guidelines Mean for Patients and Surgical Teams
-
Nov 21, 2026, 08:17Doaa El Demerdash: The Bridge Meeting Fosters International Dialogue on Hemophilia Care
-
Nov 21, 2026, 08:16Emily Branchard: Uncoupling Anticancer and Antiplatelet Effects of Dipyridamole Analogs
-
Nov 21, 2026, 08:10Rory R Koenen: Xin Xin Earns PhD for Research on Extracellular Vesicles and Vascular Inflammation
-
Nov 21, 2026, 08:06Andrew Hill: How Do You Build Loyalty when Financial Incentives Are off the Table?
-
Nov 21, 2026, 08:00Kevin Dean: How Leptin Receptor Positive Stromal Cells Regulate Platelet Production